Your browser doesn't support javascript.
loading
A multi-country analysis of COVID-19 hospitalizations by vaccination status.
Gonçalves, Bronner P; Jassat, Waasila; Baruch, Joaquín; Hashmi, Madiha; Rojek, Amanda; Dasgupta, Abhishek; Martin-Loeches, Ignacio; Reyes, Luis Felipe; Piubelli, Chiara; Citarella, Barbara Wanjiru; Kartsonaki, Christiana; Lefèvre, Benjamin; López Revilla, José W; Lunn, Miles; Harrison, Ewen M; Kraemer, Moritz U G; Shrapnel, Sally; Horby, Peter; Bisoffi, Zeno; Olliaro, Piero L; Merson, Laura.
Affiliation
  • Gonçalves BP; ISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, UK. Electronic address: bronnergoncalves@gmail.com.
  • Jassat W; National Institute for Communicable Diseases, Johannesburg, South Africa; Right to Care, Pretoria, South Africa.
  • Baruch J; ISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
  • Hashmi M; Critical Care Asia and Ziauddin University, Karachi, Pakistan.
  • Rojek A; ISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
  • Dasgupta A; Doctoral Training Centre, University of Oxford, Oxford, UK; Department of Biology, University of Oxford, Oxford, UK.
  • Martin-Loeches I; Department of Intensive Care Medicine, Multidisciplinary Intensive Care Research Organization (MICRO), St James's Hospital, Leinster, Dublin, Ireland; Pulmonary Intensive Care Unit, Respiratory Institute, Hospital Clinic of Barcelona, IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer
  • Reyes LF; Unisabana Center for Translational Science, School of Medicine, Universidad de La Sabana, Chía, Colombia.
  • Piubelli C; Department of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.
  • Citarella BW; ISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
  • Kartsonaki C; MRC Population Health Research Unit, Clinical Trials Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Lefèvre B; Université de Lorraine, CHRU-Nancy, Service des Maladies Infectieuses et Tropicales, Nancy, France; Université de Lorraine, APEMAC, Nancy, France.
  • López Revilla JW; Instituto Nacional del Niño San Borja and Facultad de Ciencias de la Salud, Universidad Científica del Sur, Lima, Peru.
  • Lunn M; ISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
  • Harrison EM; Centre for Medical Informatics, The University of Edinburgh, Usher Institute of Population Health Sciences and Informatics, Edinburgh, UK.
  • Kraemer MUG; Department of Biology, University of Oxford, Oxford, UK; Pandemic Sciences Institute, University of Oxford, Oxford, UK.
  • Shrapnel S; Centre for Health Services Research, Faculty of Medicine, The University of Queensland, Herston, Brisbane, Australia; School of Mathematics and Physics, Faculty of Science, The University of Queensland, St Lucia, Brisbane, Australia.
  • Horby P; ISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
  • Bisoffi Z; Department of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.
  • Olliaro PL; ISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
  • Merson L; ISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
Med ; 4(11): 797-812.e2, 2023 11 10.
Article in En | MEDLINE | ID: mdl-37738979
BACKGROUND: Individuals vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), when infected, can still develop disease that requires hospitalization. It remains unclear whether these patients differ from hospitalized unvaccinated patients with regard to presentation, coexisting comorbidities, and outcomes. METHODS: Here, we use data from an international consortium to study this question and assess whether differences between these groups are context specific. Data from 83,163 hospitalized COVID-19 patients (34,843 vaccinated, 48,320 unvaccinated) from 38 countries were analyzed. FINDINGS: While typical symptoms were more often reported in unvaccinated patients, comorbidities, including some associated with worse prognosis in previous studies, were more common in vaccinated patients. Considerable between-country variation in both in-hospital fatality risk and vaccinated-versus-unvaccinated difference in this outcome was observed. CONCLUSIONS: These findings will inform allocation of healthcare resources in future surges as well as design of longer-term international studies to characterize changes in clinical profile of hospitalized COVID-19 patients related to vaccination history. FUNDING: This work was made possible by the UK Foreign, Commonwealth and Development Office and Wellcome (215091/Z/18/Z, 222410/Z/21/Z, 225288/Z/22/Z, and 220757/Z/20/Z); the Bill & Melinda Gates Foundation (OPP1209135); and the philanthropic support of the donors to the University of Oxford's COVID-19 Research Response Fund (0009109). Additional funders are listed in the "acknowledgments" section.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Type of study: Prognostic_studies Limits: Humans Language: En Journal: Med Year: 2023 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Type of study: Prognostic_studies Limits: Humans Language: En Journal: Med Year: 2023 Document type: Article Country of publication: